5 Biomarkers Everyone Should Track After 30 (And Why Your Standard Panel Misses Them)

There's a specific kind of frustration that brings people here.

You went in for your physical. They drew blood. A week later the portal message arrived: Everything looks normal. And you're standing there at 42, sleeping badly, watching your waistband move in one direction, running at what feels like 70% — holding a piece of paper that says you're fine.

Both things are true. Your labs probably were normal by the reference ranges used. Those ranges just aren't answering the question you're asking.

Here's the distinction that clears most of this up. A standard panel is a screening tool. It's designed to catch disease that has already established itself, in a population, at reasonable cost. It's good at that. What it is not designed to do is detect the two-decade drift that precedes disease — the slow slide where nothing is abnormal yet and everything is trending.

That drift is the interesting part, because it's the part you can still change.

A quick word on reference ranges, because this trips up almost everyone. A "normal" range is typically built from the middle 95% of results in a reference population. It describes what's common, not what's healthy. In a population where roughly one in three adults has metabolic dysfunction, common and healthy have quietly stopped being the same thing. Being inside the range means you resemble your peers. It doesn't mean you're where you want to be.

These five markers are worth knowing. Two of them are on essentially no standard panel. One only recently became a formal guideline recommendation.

---

1. ApoB — the number that should have replaced LDL cholesterol

What it is: Apolipoprotein B is a structural protein. Every particle in your blood capable of depositing cholesterol into an artery wall — LDL, VLDL, IDL, Lp(a), remnants — carries exactly one ApoB molecule. One particle, one ApoB. So measuring ApoB counts the particles.

Why it beats LDL-C: Standard LDL cholesterol measures the cargo — how much cholesterol is being carried. ApoB counts the trucks. Those usually track together, so for most people LDL-C is a reasonable proxy.

For a meaningful minority, they don't. You can carry a large number of small, cholesterol-depleted LDL particles: high particle count, unremarkable LDL-C. This pattern clusters in exactly the people who most need to know about it — insulin resistance, elevated triglycerides, low HDL, central adiposity, type 2 diabetes. Those patients are told their cholesterol is fine while carrying elevated atherogenic particle burden.

The mechanistic logic is straightforward. Atherosclerosis begins when an ApoB-containing particle crosses the endothelium and gets retained in the artery wall. The determining factor is how many particles collide with that wall over time. It's a traffic problem. Counting trucks beats estimating average cargo.

Where the guidelines now stand: The 2026 ACC/AHA dyslipidemia guideline says ApoB may be used to assess the risk that remains in patients with cardiovascular-kidney-metabolic syndrome, type 2 diabetes, elevated triglycerides, or established cardiovascular disease who have already reached their LDL-C goal. That's a narrower endorsement than lipidologists have argued for, but it's a real one — and it names precisely the discordant group above.

Roughly how to read it:

These are orientation, not treatment thresholds. What target applies to you depends on your overall risk, which the 2026 guideline now calculates using the PREVENT equations rather than the older pooled cohort equations. Under PREVENT, ten-year risk sorts into low (<3%), borderline (3–<5%), intermediate (5–<10%) and high (≥10%), with LDL-C goals of under 100 mg/dL at borderline-to-intermediate risk, under 70 at high risk, and under 55 in very-high-risk secondary prevention.

How to get it: ApoB is a standardized, inexpensive, widely available blood test. It is simply not ordered by default. You generally have to ask.

---

2. Lp(a) — measure once, then you know

What it is: Lipoprotein(a) is an LDL particle with an extra protein, apolipoprotein(a), attached. Your level is roughly 80–90% genetically determined, set at birth, and essentially stable for life. Diet barely moves it. Exercise barely moves it. Statins don't lower it and can nudge it slightly upward.

Why it matters: Elevated Lp(a) is one of the most common inherited cardiovascular risk factors, affecting an estimated one in five people worldwide — and the overwhelming majority have never been tested. It's independently associated with heart attack, stroke, and calcific aortic valve disease. It's a meaningful part of the explanation for the person who has a cardiac event in their fifties with an otherwise unremarkable lipid panel and clean habits.

The 2026 change: The updated ACC/AHA guideline now recommends measuring Lp(a) at least once in adulthood. That's a substantial shift from prior guidance, which reserved testing for selected high-risk patients. Levels at or above 125 nmol/L (roughly 50 mg/dL) associate with about 1.4-fold increased long-term risk; at or above 250 nmol/L, risk roughly doubles or more.

What to do if it's high. There is still no approved therapy that specifically lowers Lp(a) and has been shown to reduce events — and the first outcome trial to report was a setback. In September 2026, the Lp(a)HORIZON trial found that pelacarsen lowered Lp(a) in more than 8,300 people with established cardiovascular disease but did not reduce heart attacks, strokes or cardiovascular deaths compared with placebo. Other Lp(a)-lowering drugs are still in outcome trials, and whether they fare differently is an open question.

Which raises the fair question — why test for something you can't treat? Three reasons, and they're good ones:

1. It changes how aggressively you manage everything else. High Lp(a) doesn't get lowered, but it raises your total risk, and that justifies driving ApoB and blood pressure lower than you otherwise would.
2. It's family information. Lp(a) is inherited in a straightforward pattern. Your result is relevant to your siblings, your parents, and your children.
3. It reframes an otherwise confusing risk picture. Knowing why a family history looks the way it does changes decisions.

How to get it: A single blood test. Request it in nmol/L, which measures particle number and is less distorted by particle size variation than mg/dL. You need it once. Not annually — once.

---

3. Fasting insulin — the earliest warning you can get

What it is: How much insulin your pancreas is secreting in the fasted state to hold your blood glucose where it is.

Why it's the most underused test on this list: Metabolic dysfunction has a long prodrome, and it runs in a predictable order.

For years — often a decade or more — your cells become progressively less responsive to insulin. Your pancreas compensates by producing more. Because it compensates successfully, your fasting glucose stays normal. Your HbA1c stays normal. Every marker on your standard panel stays normal, right up until the pancreatic beta cells can no longer keep pace. Only then does glucose rise, and by that point you are years into the process with meaningful beta-cell function already lost.

Fasting glucose tells you whether compensation is still working. Fasting insulin tells you how hard your body is working to keep it that way. That's the difference between a warning light and a breakdown.

Roughly how to read it:

Many labs report a reference range extending to 25 µIU/mL as "normal." That range describes the population, and the population is not doing well.

Better still, calculate HOMA-IR. Combine fasting insulin with fasting glucose:

HOMA-IR = (fasting insulin in µIU/mL × fasting glucose in mg/dL) ÷ 405

Under 1.0 is excellent. Under 2.0 is generally reasonable. Above 2.5–3.0 suggests meaningful insulin resistance. It's free — the arithmetic uses two numbers you already have.

Why this matters beyond diabetes: Insulin resistance is upstream of a great deal. It drives the small-dense-LDL pattern that makes ApoB and LDL-C diverge. It's central to metabolic dysfunction-associated fatty liver disease. It's strongly associated with hypertension, with polycystic ovary syndrome, and with the erectile dysfunction that often shows up years before a cardiac diagnosis. It's also the single most modifiable item on this entire list. Resistance training, protein adequacy, sleep, and fat loss all move it, sometimes quickly.

How to get it: Fasting insulin is inexpensive and routinely omitted. Fast 8–12 hours, water only.

---

4. hs-CRP — the inflammation signal

What it is: High-sensitivity C-reactive protein, a marker of systemic inflammation. The "high-sensitivity" assay detects the low-grade chronic elevations relevant to cardiovascular risk, as opposed to the large spikes that accompany acute infection.

Why it matters: Atherosclerosis is not purely a lipid storage problem; it's an inflammatory response to retained lipid particles. Two people with identical ApoB can have quite different outcomes depending on the inflammatory environment those particles land in. The CANTOS trial demonstrated the principle directly: an anti-inflammatory drug with no lipid-lowering effect whatsoever reduced cardiovascular events. Not every anti-inflammatory drug tested since has repeated that result, but the principle — that inflammation contributes to risk independently of lipids — has held.

Roughly how to read it:

The critical caveat: hs-CRP is nonspecific. A cold, a dental infection, a hard training session in the preceding days, an autoimmune flare, or recent injury will all raise it. A single elevated value means very little. Two measurements at least two weeks apart, away from acute illness, mean considerably more. Anything above 10 mg/L should be treated as acute inflammation and rechecked rather than interpreted as cardiovascular risk.

What moves it: Visceral fat is metabolically active tissue that secretes inflammatory cytokines, so fat loss lowers hs-CRP reliably. Sleep, alcohol reduction, periodontal health, and aerobic training all contribute.

---

5. ALT — the marker hiding in plain sight

What it is: Alanine aminotransferase, a liver enzyme. It's on nearly every basic metabolic panel you've ever had. It's also the one people skim past.

Why it belongs here: Metabolic dysfunction-associated steatotic liver disease — MASLD, formerly called non-alcoholic fatty liver disease — affects roughly 30% of adults globally and the large majority don't know. It is closely coupled to insulin resistance, and it is the metabolic problem people are least likely to be told about, because the early stage is silent and the enzyme elevation is mild.

The reference range is the issue. Many labs still flag ALT only above 40–55 U/L, ranges derived decades ago from populations that included a great many people with undiagnosed fatty liver. Research using healthier reference populations suggests the upper limit of genuinely normal sits closer to 30 U/L for men and 19–25 U/L for women.

So an ALT of 38 gets reported as normal, and it may not be.

How to read it in context: ALT is most informative alongside the rest of the picture. ALT in the high-20s-to-30s together with elevated fasting insulin, elevated triglycerides, low HDL, and central adiposity is a recognizable pattern. Isolated mild elevation with clean metabolic markers is a different situation and has other causes worth checking — medications, alcohol, viral hepatitis, and less common conditions.

Why it earns a spot: Because it costs nothing extra. It's already on your panel. Reading it against a tighter threshold rather than the lab's flag is free information.

---

The sixth one, which isn't a blood test

If you'll allow one addition: VO₂max, your body's maximum rate of oxygen utilization during intense exercise.

It belongs on any list of this kind because the association with all-cause mortality is among the strongest in the literature — comparable to or exceeding smoking, hypertension, and diabetes as a predictor. Low cardiorespiratory fitness is not a soft risk factor.

It also has a property no blood marker has: it maps directly onto what your life will feel like at 75. VO₂max declines roughly 10% per decade after 30, faster if you're sedentary. Everyday activities require a fairly fixed oxygen cost. As your ceiling drops toward that fixed cost, the ordinary things — stairs, carrying groceries, keeping up on a walk — start consuming a larger share of your maximum, and eventually stop being possible. Building headroom now is precisely the mechanism by which capacity is banked and later spent.

Formal testing uses a metabolic cart at an exercise physiology lab. Modern wearables estimate it reasonably well for tracking trends, which is usually enough.

---

How to actually use this

Get the tests. Ask your primary care physician to add ApoB, Lp(a), fasting insulin, and hs-CRP to your next panel. ALT is almost certainly already there. Most are inexpensive; coverage varies, and self-pay is often modest. Direct-to-consumer lab services can order them in most states if your physician won't.

Know your baseline before you change anything. A single result is a data point. Two results six months apart are a trajectory, and trajectory is the useful thing. Test before you start any significant intervention, not after.

Interpret them together. No marker on this list means much alone. High ApoB with clean insulin, normal hs-CRP, and normal ALT is a different situation than the same ApoB with HOMA-IR of 3.5 and ALT of 35. The pattern is the diagnosis, and this is exactly where an experienced clinician earns their keep.

Retest on a sensible schedule. Lp(a) once, ever. ApoB, fasting insulin, hs-CRP, and ALT every 6 to 12 months, or 8 to 12 weeks after a meaningful change in medication, training, or body composition.

---

The point

Your body maintains a reserve — metabolic flexibility, cardiorespiratory capacity, lean mass, arterial health — that you build in your thirties and forties and spend in your sixties and seventies. Standard screening is designed to detect the spending. These markers show you the balance while you can still add to it.

Longevity isn't added at the end of your life. It's banked in the middle.

Reserve's comprehensive lab panel is in development and not yet available. When it launches it will cover these markers and more, with clinician interpretation and a structured retest cadence. In the meantime, the list above works with any lab — take it to your physician and ask.

---

Frequently asked questions

If I can only add one test, which? Fasting insulin. It's the earliest signal, the most modifiable, and the one most likely to be abnormal in someone who feels off but was told their labs are fine.

Do I need to fast? For fasting insulin and HOMA-IR, yes — 8 to 12 hours, water only. ApoB and Lp(a) are reliable non-fasting. Draw everything together while fasted for simplicity.

Will insurance cover these? Coverage varies by plan and by whether a diagnosis code supports the order. Lp(a) coverage has been improving as guidelines strengthened. Self-pay costs for the full set are typically modest — often less than a month of most gym memberships.

My doctor says these aren't necessary. Who's right? Both, in a sense. Your physician is applying population screening guidelines, which are built around cost-effectiveness across millions of people. You're asking an individual optimization question. They're different questions. It's reasonable to say you understand it isn't standard screening and you'd like the information anyway.

Is Lp(a) worth testing if nothing treats it? Yes. The first Lp(a)-lowering drug to finish an outcome trial didn't reduce events, but the reasons to test never depended on one: a high result changes how aggressively you manage every other modifiable risk factor, and it's information your family needs.